Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TET2 | Q6N021 | 6/20 | 0.43 |
| ▸ | TET3 | O43151 | 2/20 | 0.43 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.43 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 2/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | PGK2 | P07205 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14920141 | 0.98 | SMN1; SMN2 (0.48) | SMN1; SMN2TET2TET3TET1OR51E2 | |
| SCHEMBL11219458 | 0.93 | SMN1; SMN2 (0.57) | SMN1; SMN2TET2TET3TET1OR51E2 | |
| SCHEMBL28219168 | 0.87 | SMN1; SMN2 (0.43) | SMN1; SMN2TET2TET3TET1OR51E2 | |
| SCHEMBL6753717 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2TET2TET3TET1OR51E2 | |
| SCHEMBL27210192 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2TET2TET3TET1OR51E2 | |
| SCHEMBL2036591 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2TET2TET3TET1OR51E2 | |
| SCHEMBL9306134 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2TET2TET3TET1OR51E2 | |
| SCHEMBL6863771 | 0.83 | SMN1; SMN2 (0.52) | SMN1; SMN2TET2TET3TET1OR51E2 | |
| SCHEMBL28786289 | 0.83 | SMN1; SMN2 (0.52) | SMN1; SMN2TET2TET3TET1OR51E2 | |
| SCHEMBL11094951 | 0.82 | TET2 (0.47) | SMN1; SMN2TET2TET3TET1OR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116438295-A | Methods and compositions for culturing pluripotent cell suspensions | 生命技术公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2021215852-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION | (주)셀트리온 (KR) | 2021-10-28 | — | — | WO | disclosed |
| CN-105334283-B | Simultaneous Determination reconstituted tobacco oxalate, amber acid radical, the sample-pretreating method of sulfate radical and phosphate radical | 广东中烟工业有限责任公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-105372371-A | Ion chromatography method for simultaneous determination of oxalic ion, succinate ion, sulfate ion and phosphate ion in reconstituted tobacco and application thereof | CHINA TOBACCO GUANGDONG IND CO | 2016-03-02 | — | — | CN | disclosed |
| CN-105334283-A | Sample pretreatment method for simultaneous determination of oxalic acid, succinic acid, sulfuric acid and phosphate radicals in regenerated tobacco leaves through ion chromatography | CHINA TOBACCO GUANGDONG IND CO | 2016-02-17 | — | — | CN | disclosed |
| EP-2344487-A1 | HEPATITIS C INHIBITOR COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2011-07-20 | — | — | EP | disclosed |
| EP-2235173-A2 | POLYPEPTIDES HAVING CELLULOLYTIC ENHANCING ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME | Novozymes A/S (DK) | 2010-10-06 | — | — | EP | disclosed |
| WO-2010034105-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| WO-2009085935-A2 | POLYPEPTIDES HAVING CELLULOLYTIC ENHANCING ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME | NOVOZYMES A/S (DK) | 2009-07-09 | — | — | WO | disclosed |